Coherus Sets $15M Quarterly Sales Goal for LOQTORZI by Q1 2026
CHRS aims to achieve $15M in quarterly LOQTORZI sales by early 2026, leveraging its role in nasopharyngeal cancer treatment. Coherus BioSciences targets $15M in quarterly sales for its LOQTORZI therapy by Q1 2026, positioning the drug as a key revenue driver in nasopharyng